Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | ASCO 2020: updates in myeloma

Jesús Berdeja • 26 May 2020
ASCO 2020
Multiple Myeloma

Jesus Berdeja, MD, Director of Myeloma Research, Sarah Cannon Research Institute, Nashville, TN, tells us what data to look out for in myeloma at the upcoming ASCO 2020 meeting.

More from Jesús Berdeja

1:22
Multiple myeloma highlights at ASH 2020
Jesús Berdeja • 11 Dec 2020
2:38
CRB-402 study update: T-cell phenotypes in myeloma
Jesús Berdeja • 11 Dec 2020
1:55
Impact of age on ide-cel efficacy in the KarMMa trial
Jesús Berdeja • 11 Dec 2020
4:10
Update on CARTITUDE-1: CAR-T in RRMM
Jesús Berdeja • 26 May 2020

Related Videos

3:54
Cilta-cel as a potential new SoC for R/R multiple myeloma: insights from the CARTITUDE-4 trial
Roberto Mina • 23 Apr 2024
1:41
CRS and neurotoxicity in bispecific antibody and CAR-T therapy for multiple myeloma
Eden Biltibo • 15 Apr 2024
0:36
The recent expanded FDA approval of cilta-cel and ide-cel into earlier lines of myeloma treatment
Sergio Giralt • 16 Apr 2024
1:48
Tackling underrepresentation of minorities in CAR-T clinical trials
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals